Long-term effectiveness and safety of liraglutide in clinical practice

Minerva Endocrinologica

Volumn 38, Issue 1, 2013, Pages 103-112

  Ponzani, P ^a  

^a Ospedale La Colletta   (Italy)

Author keywords

Diabete mellitus; Diabete mellitus, therapy; Hypoglycemia

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; SULFONYLUREA;

ADOPTION; ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE DURATION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTPATIENT DEPARTMENT; PATIENT SAFETY; PHENOTYPE; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; AMBULATORY CARE FACILITIES; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84876571220     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Rossi MC, Nicolucci A. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Acta Biomed 2009;80:93-101.
2. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202.
3. Russell-Jones D. Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol 2009;297:137-40.
4. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001;25:781-92.
5. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H et al. Glucagon-like peptide 1 inhibits cell apoptosis and improbe glucose responsiveness of freshly isolated human islets. Endocrinology 2003;144:5149-58.
6. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al.; LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
7. Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, Strand J et al.; LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78.
8. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al.; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;3:84-90.
9. Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30.
10. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al.; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs. insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55.
11. Buse J, Rosenstock J, Sesti G, Montanya E, Brett JH, Zychma M et al., for the LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallelgroup, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
12. Frid A, Hermansen K, Nauck M, Shah N, Tankova T, Mitha I et al. Long-term sustained glycaemic control with liraglutide and glimepiride (both plus metformin), with added benefits of weight loss and less hypoglycaemia with liraglutide: 2-year LEAD-2 data. Diabetologia 2009;52(Suppl. 1).OP-3.
13. Garber AJ, Henry R, Ratner R, Hale P, Chang CT, Bode B. Monotherapy with liraglutide, a once-daily human GLP-1 analog, provides sustained reductions in A1c, FPG, and weight compared with glimepiride in type 2 diabetes: LEAD-3 mono 2-year results. Diabetes 2009;58(Suppl. 1):162-OR.
14. Fonseca V, Madsbad S, Falahati A, Zychma M, Plutzky J. Once-daily human GLP-1 analog liraglutide reduces systolic blood pressure - a meta-analysis of six clinical trials (LEAD). Diabetes 2009;58(Suppl. 1):545-P.
15. Holst JJ, Nauck M, Brett J, Falahati A, Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomized clinical trials. Diabetologia 2009;52(Suppl. 1):P-736.
16. Zinman B, Buse J, Falahati A, Moses A, Gough S. Attaining a clinically relevant composite endpoint of HbA1c >7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: meta-analysis of the LEAD studies. Diabetologia 2009;52(Suppl. 1):OP-743.
17. Ponzani P, Corsi A. Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide. Minerva Endocrinol 2012;37:1-8.